PHASES Migraine Study in Phoenix: What an Observational Ubrogepant Study Can and Cannot Tell You

When a person with migraine hears about a research opportunity, one of the first questions is often simple: “Will this study change my treatment?” The answer depends on the type of research. Arizona Neuroscience Research currently lists PHASES, study P25-590, as an observational study involving adults with migraine who use ubrogepant, also known by the brand name Ubrelvy. The public description says the study looks at changes in migraine-attack severity in people using oral ubrogepant.

This Phoenix guide explains what an observational migraine study generally involves, what it does not promise, and what questions are worth asking before sharing health information or scheduling a screening. It is educational only. It cannot determine eligibility, tell someone whether ubrogepant is appropriate, or replace advice from the clinician who manages that person’s migraine care. For the current local listing, visit ANR’s Current Studies page or contact the site through Volunteer Today.

What is the PHASES migraine study?

Arizona Neuroscience Research lists PHASES (P25-590) as an observational study sponsored by AbbVie. It is designed to assess changes in migraine-attack severity in adults with migraine who are using oral ubrogepant. Unlike a study that assigns a new experimental treatment according to a fixed protocol, an observational study focuses on collecting information about experiences in a defined group. It may use questionnaires, headache records, medication-use details, visit information, or other approved study measures.

The public listing is a starting point, not the entire protocol. The site can explain current enrollment status, the length of participation, what information is collected, how often the team contacts participants, and whether a person’s treatment history meets the present criteria. It is important to ask about the actual study procedures instead of assuming that every observational study follows the same pattern.

Observational study versus treatment trial: the key difference

Research studies have different goals. Some interventional trials test a study treatment, compare treatments, or assign participants to a planned schedule. Observational research usually does not direct routine medical treatment in the same way. It follows and records real-world information from people who meet the study criteria. The word “observational” does not mean that the research lacks safeguards. It means that the central question is about observing outcomes, patterns, or experiences rather than proving that a newly assigned intervention works for every participant.

For PHASES, the important public point is that the study concerns people using ubrogepant for migraine. The research team can clarify whether participants must already have a prescription, how medication use is documented, whether the study changes anything about routine care, and what happens if someone’s doctor changes a treatment plan during participation. Do not start, stop, share, or change medication in order to join a study unless your own prescriber and the research team provide specific instructions.

A brief, practical look at migraine

Migraine is more than “a bad headache.” It is a neurologic condition that can involve head pain, nausea, sensitivity to light or sound, vomiting, visual symptoms, dizziness, fatigue, or difficulty thinking clearly. Attack patterns vary. Some people experience occasional disabling attacks, while others have symptoms on many days each month. Stress, sleep disruption, dehydration, weather shifts, meals, hormonal changes, and other factors may be relevant for one person and less relevant for another.

Because migraine is variable, research often asks participants to report what happened around individual attacks. A clear record can capture more than pain intensity. It may note when symptoms began, how long they lasted, whether nausea or light sensitivity occurred, which medicine was taken, whether a second dose or other medicine was needed, and how the attack affected work, family activities, driving, or sleep. None of these details prove a treatment response by themselves. Together, however, they can help researchers understand patterns in a carefully defined group.

What is ubrogepant?

Ubrogepant is a prescription oral medicine used for the acute treatment of migraine attacks in adults. Acute treatment means a medicine taken to address an attack, rather than a medicine intended for scheduled prevention. Whether it is appropriate for a particular person depends on their health history, medications, pregnancy considerations, liver and kidney health, and other factors. A research website cannot answer that personal question.

If you already take ubrogepant, your prescriber or pharmacist remains the right source for medication instructions, possible interactions, and what to do if your migraine pattern changes. A research coordinator can explain how PHASES records medication use and which details the study needs. The manufacturer’s PHASES study page and its current registry information are additional places to review approved study details.

Why real-world migraine information matters

Clinical research can use several kinds of evidence. Highly controlled trials are useful for answering specific questions under planned conditions. Observational research can add information about what people report during their ordinary lives, within the limits of the design. An adult may have attacks at work, at home, while caring for a child, during travel, or in the middle of an Arizona heat wave. A research project can ask how symptoms and treatment use look outside a highly controlled setting.

That does not make an observational study a guarantee of benefit. A report of improvement, worsening, or no change may reflect many factors beyond any one medicine: the natural ups and downs of migraine, sleep, illness, hormonal patterns, stress, other treatment changes, or how consistently data were recorded. Researchers use study methods to interpret information carefully. Participants help by reporting honestly and by asking when they are unsure how to complete a record.

What might participation involve?

Only the site can describe the current PHASES protocol, but people considering an observational migraine study can reasonably ask about several practical topics. There may be an initial screening to confirm basic criteria. There may be questionnaires about migraine history, medication use, health conditions, and current care. Some studies ask volunteers to keep a diary or respond to digital prompts. Others may include telephone follow-up, clinic visits, or both. Ask whether a participant needs a smartphone, computer, or paper record and what support is available if technology is difficult.

Before you agree to anything, request a clear explanation of the time commitment. Ask how long participation lasts, how many contacts are expected, whether missed entries can be corrected, how travel or parking is handled, and whether any reimbursement is available. Also ask whether the team will request medical records or communicate with your treating clinician. These questions are appropriate before screening and help prevent surprises later.

How to prepare for a screening conversation

A short preparation list can make the first discussion more efficient. Have the name and dose of current migraine medicines available, including prescription acute treatments, preventive treatments, over-the-counter pain relievers, vitamins, and supplements. Be ready to describe how often attacks occur, how long they usually last, and how they affect your ability to function. If you use a headache app or calendar, you do not need a perfect report, but a few weeks of information may help you speak clearly about your usual pattern.

Bring up other health conditions and medicines honestly. Eligibility criteria exist to protect participants and to make research findings meaningful. A coordinator may ask about pregnancy, prior treatments, cardiovascular history, kidney or liver conditions, recent study participation, or other details that are relevant to the protocol. An answer that makes someone ineligible is not a judgment about their health; it simply means the study is not the right research fit at that time.

Questions to ask before deciding

• Is the PHASES migraine study currently enrolling at the Phoenix site?
• Do I need to already be prescribed ubrogepant, and does the study supply any medication?
• Does participation change the treatment plan made with my usual clinician?
• What information will I be asked to record during migraine attacks?
• How many appointments, phone calls, or online surveys are expected?
• What happens if I miss a diary entry, change doctors, or my migraine treatment changes?
• How is my health information stored, and who can access it?
• Are there costs, reimbursement details, or travel considerations I should understand?
• Who should I call with a medication question or a new symptom during the study?

Write down the answers. Research consent is a process, not a single signature. You can take time to review materials, discuss participation with your own clinician or family, and decide whether the commitment makes sense for you.

Keeping a useful migraine record

Accurate records are valuable to both patient care and research. The goal is not perfection; it is a realistic picture of what happened. If PHASES or your clinician asks for a migraine diary, record information as close to the attack as practical. Trying to reconstruct an entire month from memory is difficult, especially when attacks affect concentration.

Details that may be helpful to track

• Date and approximate time symptoms began
• Head pain severity and other symptoms, such as nausea or light sensitivity
• Possible triggers or circumstances, if you noticed any
• Medication taken and the time it was taken
• Whether symptoms changed after treatment
• Impact on work, household responsibilities, sleep, or planned activities
• Any urgent symptoms or reasons you sought immediate care

A diary should not become a source of pressure. If an entry is missed, tell the study team rather than guessing. Honest reporting, including days when no attack occurs or when a treatment does not seem to help, is more useful than trying to make a record look complete.

Privacy and informed consent

Before participating, you should receive information about what data the study collects, how it is coded or protected, who may review it, and how long it may be retained. The consent document should also explain the purpose of the research, potential discomforts, alternatives, compensation if offered, and whom to contact with questions. Ask for explanations in plain language if any section is unclear.

Taking part is voluntary. A person may decide that the time commitment, data collection, or study procedures are not a good fit. That choice should not affect access to ordinary medical care. Similarly, being screened does not guarantee enrollment, and enrollment does not guarantee a particular experience or outcome.

When migraine symptoms need urgent care

Most migraine attacks are not emergencies, but a familiar diagnosis should never be used to dismiss a dangerous new symptom. Seek emergency evaluation or call 911 for a sudden severe headache that peaks quickly, a new headache with fainting, seizure, confusion, trouble speaking, new weakness or numbness on one side, sudden vision loss, severe neck stiffness with fever, head injury, or another potentially life-threatening symptom. These symptoms can have causes other than migraine and need prompt assessment.

If a headache is different from your usual pattern, lasts longer than expected, follows a significant change in health, or comes with concerning symptoms, contact a clinician for individualized guidance. If you are enrolled in a study, follow the site’s instructions for reporting adverse events, but do not delay urgent care while waiting for a research response.

Frequently asked questions

Is PHASES a clinical trial?

PHASES is listed by Arizona Neuroscience Research as an observational migraine study. The site can explain its specific design, data collection, and current status.

Will the study prescribe ubrogepant to me?

Do not assume that it will. Ask the research team whether participants must already be using ubrogepant, whether any medication is provided, and how routine treatment decisions are handled.

Can I join if I use another migraine treatment too?

Possibly or not, depending on the current protocol. The research team needs a complete and accurate medication list to evaluate this question.

Will my migraine get better if I participate?

No research study can promise individual symptom improvement. Observational research collects information; it does not guarantee a particular treatment response or eligibility decision.

Where can I confirm current availability in Phoenix?

Check the ANR Current Studies page and submit a question through Volunteer Today. Availability and eligibility may change.

Take the next step thoughtfully

If you are an adult with migraine who already uses ubrogepant and want to understand the PHASES research opportunity, contact Arizona Neuroscience Research through Volunteer Today. A first conversation can clarify current enrollment, possible screening steps, and whether the study’s time commitment fits your life. Keep your regular migraine-care team involved in decisions about medicines and symptom changes.

Educational disclaimer: This article provides general educational information and is not medical advice, a diagnosis, medication guidance, or a recommendation to join a study. Study availability, eligibility, procedures, and risks are determined by the current protocol and research staff. Speak with your treating clinician about personal migraine care.